Atomi Financial Group Inc. grew its holdings in Sanofi (NASDAQ:SNY – Free Report) by 26.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,932 shares of the company’s stock after acquiring an additional 4,189 shares during the quarter. Atomi Financial Group Inc.’s holdings in Sanofi were worth $1,149,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of the business. POM Investment Strategies LLC acquired a new stake in shares of Sanofi during the second quarter worth $25,000. Register Financial Advisors LLC bought a new stake in shares of Sanofi in the first quarter valued at about $29,000. Larson Financial Group LLC lifted its holdings in shares of Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares in the last quarter. Palisade Asset Management LLC bought a new stake in shares of Sanofi in the first quarter valued at about $31,000. Finally, Arrow Financial Corp bought a new stake in shares of Sanofi in the second quarter valued at about $35,000. Institutional investors and hedge funds own 10.04% of the company’s stock.
Sanofi Stock Up 0.2 %
NASDAQ:SNY opened at $54.85 on Wednesday. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97. The firm has a market capitalization of $138.92 billion, a price-to-earnings ratio of 27.56, a price-to-earnings-growth ratio of 1.58 and a beta of 0.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock’s 50 day moving average price is $55.58 and its two-hundred day moving average price is $51.19.
Analyst Upgrades and Downgrades
SNY has been the topic of a number of research reports. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.
Get Our Latest Stock Report on SNY
Sanofi Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
- Five stocks we like better than Sanofi
- Stock Market Sectors: What Are They and How Many Are There?
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Why Are Stock Sectors Important to Successful Investing?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.